Regeneron Pharmaceuticals has acquired Oxular, a UK-based biotech specializing in ocular drug delivery technology, to strengthen its gene therapy development program. Former Oxular CEO Mark Gaffney disclosed the deal in a LinkedIn post, and Regeneron has confirmed the acquisition. Financial terms remain undisclosed.

The acquisition brings Oxular’s lead candidate, OXU-001, into Regeneron’s pipeline. OXU-001 is a specialized dexamethasone formulation delivered to the posterior suprachoroidal space using biodegradable Oxuspheres and a proprietary illuminated microcatheter. Currently in phase 2 trials, OXU-001 is being developed as a once-yearly treatment for diabetic macular edema.